Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
6
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
6
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
6
×
san diego blog main
6
×
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
astrazeneca
clinical trials
eli lilly
fda
johnson & johnson
merck
pfizer
biogen
cancer
cancer immunotherapy
celgene
What
bio
roundup
drug
news
biotech
companies
fda
nash
prices
seven
alzheimer’s
annual
approval
approved
assessed
attention
august
away
biogen’s
biopharma
biopharmaceutical
bringing
busy
car
celgene
ceos
colleagues
communities
conference
convo
days
dc
decisions
devices
digital
disease
drugs
earlier
epidemic
esmo
Language
unset
Current search:
abbvie
×
" san diego blog main "
×
" raleigh-durham top stories "
×
" bristol-myers squibb "
×
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More